Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.
Lubiprostone activates ClC-2 chloride channels in epithelia. It is approved for treatment of chronic idiopathic constipation in adults and constipation-predominate irritable bowel syndrome in women. We tested a hypothesis that lubiprostone can reverse the constipating action of morphine and investigated the mechanism of action. Short-circuit current (Isc) was recorded in Ussing chambers as a marker for chloride secretion during pharmacological interactions between morphine and lubiprostone. Measurements of fecal wet weight were used to obtain information on morphine-lubiprostone interactions in conscious mice. Morphine decreased basal Isc, with an IC(50) of 96.1 nM. The action of dimethylphenylpiperazinium (DMPP), a nicotinic receptor agonist that stimulates neurogenic Isc, was suppressed by morphine. Lubiprostone applied after pretreatment with morphine reversed morphine suppression of both basal Isc and DMPP-evoked chloride secretion. Electrical field stimulation (EFS) of submucosal neurons evoked biphasic increases in Isc. Morphine abolished the first phase and marginally suppressed the second phase. Lubiprostone reversed, in concentration-dependent manner, the action of morphine on the first and second phases of the EFS-evoked responses. Subcutaneous lubiprostone increased fecal wet weight and numbers of pellets expelled. Morphine significantly reduced fecal wet weight and number of pellets. Injection of lubiprostone, 30-min after morphine, reversed morphine-induced suppression of fecal wet weight. We conclude that inhibitory action of morphine on chloride secretion reflects suppression of excitability of cholinergic secretomotor neurons in the enteric nervous system. Lubiprostone, which does not directly affect enteric neurons, bypasses the neurogenic constipating effects of morphine by directly opening chloride channels in the mucosal epithelium.
Fei
Guijun
G
Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH 43210-1218, USA.
Raehal
Kirsten
K
Liu
Sumei
S
Qu
Mei-Hua
MH
Sun
Xiaohong
X
Wang
Guo-Du
GD
Wang
Xi-Yu
XY
Xia
Yun
Y
Schmid
Cullen L
CL
Bohn
Laura M
LM
Wood
Jackie D
JD
D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000090007:CLC-2 Chloride Channels; D018118:Chloride Channels / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002713:Chlorine / Q000378:metabolism; D003248:Constipation / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D007422:Intestines / Q000187:drug effects; D015640:Ion Channel Gating / Q000187:drug effects; D000068238:Lubiprostone; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects*; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D011453:Prostaglandins / Q000378:metabolism
D000090007:CLC-2 Chloride Channels; D018118:Chloride Channels; D011453:Prostaglandins; D002713:Chlorine; D000068238:Lubiprostone; D009020:Morphine; D000527:Alprostadil
J Clin Invest. 1986 Feb;77(2):348-54
3003156
Brain Res. 1982 Jun 17;242(1):145-50
7104724
Am J Physiol. 1983 Aug;245(2):G290-6
6881351
Br J Pharmacol Chemother. 1957 Mar;12(1):119-27
13413163
Neuroscience. 1985 Oct;16(2):425-30
3001581
Neuroscience. 2003;119(1):33-42
12763066
Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G823-32
19179625
Am J Physiol. 1984 Mar;246(3 Pt 1):G263-7
6142654
Pain Physician. 2007 Mar;10(2):357-66
17387357
J Pharmacol Exp Ther. 1990 Apr;253(1):144-51
2329501
Neuroscience. 1981;6(10):1943-51
7301113
Acta Physiol Scand. 1966 Apr;66(4):509-10
5951401
Br J Pharmacol. 2008 May;154(1):126-35
18332851
Dig Dis Sci. 2009 Oct;54(10):2063-9
19657734
J Pharmacol Methods. 1990 Aug;24(1):59-71
2214801
Support Care Cancer. 2008 May;16(5):453-9
18197439
Neurogastroenterol Motil. 2008 Jan;20(1):80-93
17973634
Am J Physiol Cell Physiol. 2004 Nov;287(5):C1173-83
15213059
Gastroenterology. 2009 Sep;137(3):976-85
19454284
J Clin Invest. 1978 Nov;62(5):1039-47
711850
Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G295-301
19033530
Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G234-51
18511742
J Physiol. 1986 Dec;381:465-82
3305874
Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:17-28
15357848
Br J Pharmacol. 1977 Dec;61(4):541-9
202356
Ann N Y Acad Sci. 1988;527:326-45
2455465
Life Sci. 1989;44(16):1083-8
2704293
Gastroenterology. 1982 Jul;83(1 Pt 1):63-8
6281126
Am J Physiol. 1983 Dec;245(6):G745-50
6140858
J Physiol. 1988 Apr;398:371-90
3392679